Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Minimal Residual Disease”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Ended earlyNCT03537599
What this trial is testing

Daratumumab and Donor Lymphocyte Infusion in Treating Participants With Relapsed Acute Myeloid Leukemia After Stem Cell Transplant

Who this might be right for
Minimal Residual DiseaseRecurrent Acute Myeloid Leukemia With Myelodysplasia-Related ChangesRecurrent Adult Acute Myeloid Leukemia+1 more
Sumithira Vasu 4
Not applicableUnknownNCT06267144
What this trial is testing

Detection of Minimal Residual Disease in Resectable Stage II-IIIB Non-small Cell Lung Cancer

Who this might be right for
Lung Cancer
The First Hospital of Jilin University 20
Not applicableStudy completedNCT06000306
What this trial is testing

MRD Monitoring by Digital Droplet PCR in the Early Period After Allo-HSCT to Predict Patients at High Risk of Relapse

Who this might be right for
Measurable Residual Disease
Zhejiang University 192
Not applicableLooking for participantsNCT05196087
What this trial is testing

Non-Invasive Artificial Intelligence-Based Platform MonIToring Program (NIP IT!)

Who this might be right for
Breast CancerMelanomaGastrointestinal Neuroendocrine Tumor
University Health Network, Toronto 500
Not applicableUnknownNCT05837689
What this trial is testing

Minimal Residual Disease Quantification by Next-generation Sequencing in Pediatric B-ALL Children Patients Treated With Blinatumomab Consolidation

Who this might be right for
Acute Lymphoblastic Leukemia, Pediatric
Xiaojun Xu 20
Testing effectiveness (Phase 2)Looking for participantsNCT03737955
What this trial is testing

Fractionated Gemtuzumab Ozogamicin in Treating Measurable Residual Disease in Patients With Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia
University of Washington 36
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06652685
What this trial is testing

Molecular Subtype Combined with Early Minimal Residual Disease to Optimize the Treatment of Newly Diagnosed Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid Leukemia (AML)
Ruijin Hospital 218
Testing effectiveness (Phase 2)Ended earlyNCT02935543
What this trial is testing

CART19 in Adult Patients With Minimal Residual Disease During Upfront Treatment for ALL

Who this might be right for
Leukemia, Acute Lymphoblastic
University of Pennsylvania 1
Testing effectiveness (Phase 2)Ended earlyNCT04044560
What this trial is testing

Blinatumomab for MRD in Pre-B ALL Patients Following Stem Cell Transplant

Who this might be right for
B-cell Adult Acute Lymphoblastic LeukemiaStem Cell LeukemiaMinimal Residual Disease
University of British Columbia 8
Not applicableLooking for participantsNCT06287723
What this trial is testing

French Assessment of MRD by Liquid Biopsies in Colorectal With Liver Metastasis Patients (FRENCH.MRD.CRLM)

Who this might be right for
Colorectal CancerLiver MetastasesStage IV Colorectal Cancer+3 more
University Hospital, Montpellier 30
Testing effectiveness (Phase 2)Active Not RecruitingNCT03610438
What this trial is testing

Feasibility and Effectiveness of Inotuzumab Ozogamicin in B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
Acute Lymphoid Leukemia
Gruppo Italiano Malattie EMatologiche dell'Adulto 76
Early research (Phase 1)Ended earlyNCT01743807
What this trial is testing

Phase I Study of GNKG168 in Acute Lymphoblastic Leukemia and Acute Myelogenous Leukemia

Who this might be right for
Relapsed Acute Lymphoblastic LeukemiaRelapsed Acute Myelogenous Leukemia
Therapeutic Advances in Childhood Leukemia Consortium 4
Not applicableStudy completedNCT02010931
What this trial is testing

Retrospective Analysis of Survival in Adult MRD Positive Acute Lymphoblastic Leukemia Patients

Who this might be right for
Acute Lymphoblastic Leukemia
Amgen 310
Testing effectiveness (Phase 2)Ended earlyNCT03523429
What this trial is testing

PETHEMA-BLIN-01/PET069014 (BLIN-01)

Who this might be right for
Philadelphia Chromosome-negative or BCR-ABL-negative, CD19-positive ALL
PETHEMA Foundation 11
Testing effectiveness (Phase 2)Ended earlyNCT01088035
What this trial is testing

Carboplatin as a Radiosensitizer in Treating Childhood Ependymoma

Who this might be right for
Ependymoma
Ann & Robert H Lurie Children's Hospital of Chicago 75
Early research (Phase 1)Temporarily pausedNCT03494569
What this trial is testing

Total Marrow and Lymphoid Irradiation, Fludarabine, and Melphalan Before Donor Stem Cell Transplant in Treating Participants With High-Risk Acute Leukemia or Myelodysplastic Syndrome

Who this might be right for
Acute Lymphoblastic LeukemiaAcute Lymphoblastic Leukemia in RemissionAcute Myeloid Leukemia+5 more
City of Hope Medical Center 36
Large-scale testing (Phase 3)Study completedNCT00179829
What this trial is testing

WT1 for the Detection of Minimal Residual Disease

Who this might be right for
LeukemiaCancer
Ann & Robert H Lurie Children's Hospital of Chicago 50
Testing effectiveness (Phase 2)Looking for participantsNCT06993675
What this trial is testing

Engaging T-cells to Eliminate MRD in Newly Diagnosed Myeloma Optimizing Response With Talquetmab and Teclistamab (ROTATE)

Who this might be right for
Multiple Myeloma
Noffar Bar 50
Not applicableUnknownNCT03564977
What this trial is testing

CD19-targeted CAR-T Cell Therapy for MRD+ B-cell Malignancies After Autologous Stem Cell Transplantation

Who this might be right for
Lymphoma, B-CellLeukemia, B-CellMinimal Disease, Residual
Qingdao Central Hospital 20
Testing effectiveness (Phase 2)WithdrawnNCT03515707
What this trial is testing

Stem Cell Transplant to Treat Patients With Favorable or Intermediate Risk Minimal Residual Disease Negative Acute Myeloid Leukemia

Who this might be right for
Acute Myeloid LeukemiaMinimal Residual Disease Negativity
Fred Hutchinson Cancer Center
Next Page